Related Experiment Video
Updated: May 23, 2026
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Pretreatment with low-dose β-adrenergic antagonist therapy does not affect severity of Takotsubo cardiomyopathy
Amruth R Palla1, Amit S Dande, Joann Petrini
1Department of Internal Medicine, Division of Hospitalist, Medicine Danbury Hospital, Danbury, Connecticut 06811, USA. amruth.palla@wcthealthnetwork.org
Insights
Beta-blocker therapy does not alter Takotsubo cardiomyopathy severity. This study found no significant difference in myocardial dysfunction markers between patients on beta-adrenergic antagonists and those not. Further research is needed.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Takotsubo cardiomyopathy is transient left ventricular dysfunction triggered by stress.
- The leading hypothesis involves a surge in catecholamines.
- Obstructive coronary artery disease is absent in Takotsubo cardiomyopathy.
Purpose of the Study:
- To investigate if outpatient beta-adrenergic receptor antagonist therapy impacts Takotsubo cardiomyopathy severity.
- To compare presentation and clinical course in patients with and without prior beta-blocker use.
Main Methods:
- Retrospective analysis of 64 Takotsubo cardiomyopathy patients (2005-2011).
- Independent review of clinical records and angiograms to confirm diagnosis.
- Comparison of myocardial dysfunction markers (cardiac enzymes, LVEDP, LVEF) between beta-blocker users and non-users using Mann-Whitney U test and Student t test.
Main Results:
- 16% of patients were on beta-blockers (metoprolol or atenolol) prior to presentation.
- Beta-blocker users were significantly older (73.1 vs 66 years).
- No significant differences were observed in cardiac enzymes, LVEDP, or LVEF between groups.
Conclusions:
- Low-dose beta-adrenergic antagonist therapy does not appear to affect the severity of Takotsubo cardiomyopathy.
- Common markers of myocardial dysfunction are not altered by prior beta-blocker use.
- The study suggests beta-blockers do not modify the acute presentation of Takotsubo cardiomyopathy.
Background:
Takotsubo cardiomyopathy is a syndrome of transient left ventricular dysfunction following acute emotional or physical stress without obstructive coronary artery disease. The leading hypothesis for the etiology is stress-induced catecholamine surge.
Hypothesis:
People taking outpatient β-adrenergic receptor antagonist therapy have less-severe presentation and clinical course of Takotsubo cardiomyopathy.
Methods:
We identified patients diagnosed with Takotsubo cardiomyopathy from October 2005 to January 2011 by analyzing our cardiac-catheterization database. Clinical records and angiograms were reviewed by 2 experienced observers independently to confirm the diagnosis. We collected clinical, demographic, laboratory, and angiographic data for the identified patients. We then compared the severity of myocardial dysfunction or damage (cardiac enzymes, left ventricular end diastolic pressure, and left ventricular ejection fraction) between patients taking outpatient β-adrenergic antagonist therapy upon admission vs those who were not. Arrival and peak values for cardiac enzymes were analyzed when available. Analysis of parameters related to the severity of myocardial dysfunction or damage was conducted using the Mann-Whitney U test. Means for age were compared using the Student t test. Statistical significance was set at P < 0.05 (2-tailed).
Results:
Out of 64 patients identified, 16 (25%) were on one of 3 β-adrenergic antagonists on presentation: metoprolol succinate, metoprolol tartrate, or atenolol, with mean doses of 75 mg daily, 52.5 mg twice daily, and 37.5 mg daily, respectively. Patients on β-blockers were older (mean age 73.1 years vs 66 years; P < 0.05). There was no statistically significant difference in levels of cardiac enzymes, left ventricular end diastolic pressure, or left ventricular ejection fraction between the 2 groups.
Conclusion:
Prior therapy with low-dose β-adrenergic antagonists does not affect the severity of presentation and clinical course of Takotsubo cardiomyopathy as measured by common markers of myocardial dysfunction.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...